Ring Sulfur In The Polycyclo Ring System Patents (Class 514/324)
  • Patent number: 10376463
    Abstract: Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: August 13, 2019
    Assignee: Eyegate Pharmaceuticals, Inc.
    Inventors: Mike Jaffe, Gary Cook, Perry Calias, Michael A. Patane
  • Patent number: 9566252
    Abstract: This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: February 14, 2017
    Assignee: HORMOS MEDICAL LTD.
    Inventors: Kaija Halonen, Lauri Kangas, Michael W. DeGregorio
  • Patent number: 9475791
    Abstract: Disclosed herein are methods for treatment of estrogen-related medical disorders. The methods of treatment may comprise administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: October 25, 2016
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Gregory R. Thatcher, Debra Tonetti, Mary Ellen Molloy, Bradley Michalsen, Zihui Qin
  • Patent number: 9439895
    Abstract: Described herein are methods of treating a mammal in need of treatment for non-histaminic pruritus by administering to the mammal in need thereof a therapeutically effective amount of RS-norketotifen or a pharmaceutically acceptable salt thereof, thereby reducing the desire to scratch in the mammal. Non-histaminergic types of pruritus are resistant to treatment with selective histamine H-1-, H-2- and H-4-receptor inhibitors. In certain aspects, the non-histaminergic pruritus is associated with diabetes.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: September 13, 2016
    Assignee: BRIDGE PHARMA, INC.
    Inventors: A.K. Gunnar Aberg, Vincent B. Ciofalo
  • Patent number: 9345697
    Abstract: Described herein are methods of treating a mammal in need of treatment for non-histaminic pruritus by administering to the mammal in need thereof a therapeutically effective amount of RS-norketotifen or a pharmaceutically acceptable salt thereof, thereby reducing the desire to scratch in the mammal. Non-histaminergic types of pruritus are resistant to treatment with selective histamine H-1-, H-2- and H-4-receptor inhibitors. In certain aspects, the non-histaminergic pruritus is associated with a dermal disorder, a psychological disorder, a mental disorder, a nerve disorder, or a systemic disorder.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: May 24, 2016
    Assignee: BRIDGE PHARMA, INC.
    Inventors: A. K. Gunnar Aberg, Vincent B. Ciofalo
  • Patent number: 9333199
    Abstract: The methods disclosed herein relate to the treatment of histamine H-4-related pruritus associated with nerve disorders, by administering a combined histamine H-1 and H-4 receptor inhibitor, specifically RS-norketotifen or a pharmaceutically acceptable salt thereof. Potentiated antipruritic activity by simultaneous inhibition of histamine H-1 receptors and histamine H-4 receptors are described.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: May 10, 2016
    Assignee: BRIDGE PHARMA, INC.
    Inventors: A. K. Gunnar Aberg, Vincent B. Ciofalo
  • Patent number: 9267122
    Abstract: The present invention relates to methods of treating neurodegenerative diseases comprising administering, to a subject in need of such treatment, one or more agent that inhibits or reduces the action, including the catalytic activity, of an enzyme of the phospholipase D family, such as phospholipase D1 and/or phospholipase D2. The present invention also relates to cell-based assays which may be used to identify agents that inhibit or reduce the activity of enzymes of the phospholipase D family and that may be used in the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: February 23, 2016
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Gilbert DiPaolo, Tae-Wan Kim, Tiago Gil Oliveira
  • Patent number: 9138431
    Abstract: The methods disclosed herein relate to the treatment of histamine H-4—related pruritus, by administering a histamine H-4 receptor inverse agonist that selectively accumulates at the biophases of the disorders, specifically RS-norketotifen or a pharmaceutically acceptable salt thereof. Potentiated antipruritic activity by simultaneous inhibition of histamine H-1 receptors and histamine H-4 receptors are described.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: September 22, 2015
    Assignee: BRIDGE PHARMA, INC.
    Inventors: A. K. Gunnar Aberg, Vincent B. Ciofalo
  • Publication number: 20150139973
    Abstract: The present invention relates to an ophthalmological vehicle system for the permeation and/or for the active substance transport of ophthalmological active substances through the cornea and/or the sclera of the eye of mammals. This vehicle system assists the transport of the active substances through the cornea and/or the sclerotic tissue of the eye. The vehicle system is suitable for the prophylaxis and/or treatment of diseases of the front and/or back portion of the eye. Likewise, the present invention relates to an ophthalmological kit, comprising a special ophthalmological composition and also, as separate formulation, an ophthalmological active substance.
    Type: Application
    Filed: May 14, 2013
    Publication date: May 21, 2015
    Inventors: Ute Steinfeld, Frank Holzer, Hyeck Hee Lee, Markus Mahler
  • Publication number: 20150133433
    Abstract: A method for preventing or treating a disease selected from the group consisting of visceral pain, inflammatory pain, osteoarthritis pain, neuropathic pain, and fibromyalgia in a subject in need thereof, comprising administering to said subject an effective amount of the compound of the following formula (I) or a salt thereof: wherein R1, R2, R3, R4, R5, X and n are as described herein.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 14, 2015
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Tsukasa ISHIHARA, Kazuhiro IKEGAI, Ikumi KURIWAKI, Hiroyuki HISAMICHI, Nobuaki TAKESHITA, Ryuichi TAKEZAWA
  • Patent number: 8981119
    Abstract: The present invention is directed to compounds of Formula I: wherein R1, R2, R3, R4, R5, X and n are described herein. These compounds and their pharmaceutically acceptable salts thereof are useful as IK1 channel activators.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: March 17, 2015
    Assignee: Astellas Pharma Inc.
    Inventors: Tsukasa Ishihara, Kazuhiro Ikegai, Ikumi Kuriwaki, Hiroyuki Hisamichi, Nobuaki Takeshita, Ryuichi Takezawa
  • Patent number: 8969385
    Abstract: Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof topical ophthalmic compositions containing norketotifen.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: March 3, 2015
    Assignee: Bridge Pharma, Inc.
    Inventors: A. K. Gunnar Aberg, Keith Johnson
  • Publication number: 20150057278
    Abstract: Amido compounds are disclosed that have a formula represented by the following: and wherein Cy1, Cy2, n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.
    Type: Application
    Filed: September 10, 2012
    Publication date: February 26, 2015
    Inventors: Dan Littman, Jun R. Huh, Ruili Huang, Wenwei Huang, Erika E. Englund
  • Publication number: 20150051194
    Abstract: 8-Substituted-2,6-methano-3-benzazocines of general structure are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.
    Type: Application
    Filed: October 31, 2014
    Publication date: February 19, 2015
    Applicant: RENSSELAER POLYTECHNIC INSTITUTE
    Inventor: Mark P. WENTLAND
  • Publication number: 20150045392
    Abstract: The methods disclosed herein relate to the treatment of histamine H-4—related pruritus, by administering a histamine H-4 receptor inverse agonist that selectively accumulates at the biophases of the disorders, specifically RS-norketotifen or a pharmaceutically acceptable salt thereof. Potentiated antipruritic activity by simultaneous inhibition of histamine H-1 receptors and histamine H-4 receptors are described.
    Type: Application
    Filed: August 6, 2013
    Publication date: February 12, 2015
    Inventors: A.K. Gunnar Aberg, Vincent B. Ciofalo
  • Publication number: 20150038468
    Abstract: The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist (“ERANT”), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions.
    Type: Application
    Filed: October 20, 2014
    Publication date: February 5, 2015
    Inventors: Carol A. Feghali-Bostwick, Pamela Anne Hershberger
  • Publication number: 20150038530
    Abstract: Disclosed herein are methods of diagnosing and treating infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 5, 2015
    Inventors: Soman N. Abraham, Ashley L. St. John
  • Publication number: 20150031656
    Abstract: The present invention relates to a combination therapy for elevating testosterone levels in male mammals in which an antiestrogen or pharmaceutically acceptable salt thereof is co-administered to the mammal with an additional therapeutic agent selected from an androgen and an aromatase inhibitor. The invention is also directed to a combination therapy for treating males with hypogonadism and disorders related thereto, including reduction of muscle mass. limitation of body performance capacity, reduction of bone density, reduction of libido, reduction of potency, reduction of benign prostatic hyperplasia and infertility.
    Type: Application
    Filed: February 28, 2013
    Publication date: January 29, 2015
    Inventors: Joseph S. Podolski, Ronald D. Wiehle
  • Publication number: 20150031680
    Abstract: The present invention relates to the long-term administration of a selective estrogen receptor modulator (SERM) with a short half-life for the treatment of a variety of estrogen receptor-mediated conditions. The SERM may be administered at a concentration at or below that of a SERM with a long half-life in order to achieve an equivalent therapeutic effect.
    Type: Application
    Filed: February 14, 2013
    Publication date: January 29, 2015
    Applicant: REPROS THERAPEUTICS INC.
    Inventors: Joseph S. Podolski, Ronald D. Wiehle
  • Publication number: 20150011557
    Abstract: The invention provides novel substituted benzyl piperidine compounds according to Formula (I) as lysophosphatidic acid (LPA) receptor antagonists, their manufacture and use for the treatment of proliferative or inflammatory diseases, such as cancer, fibrosis or arthritis.
    Type: Application
    Filed: September 7, 2012
    Publication date: January 8, 2015
    Applicant: Merck Patent GmbH
    Inventors: Kai Schiemann, Wolfgang Staehle, Michael Busch, Dirk Wienke, Oliver Poeschke, Christa Burger
  • Publication number: 20150011541
    Abstract: The present invention relates to compounds having a pipecolate sulfonamide scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said pipecolate sulfonamide compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.
    Type: Application
    Filed: December 28, 2012
    Publication date: January 8, 2015
    Inventors: Ranganath Gopalakrishnan, Felix Hausch
  • Publication number: 20150005275
    Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3, L, and the subscript m are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions, and methods of treatment using the same, for the treatment of cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: May 6, 2014
    Publication date: January 1, 2015
    Inventors: Steven Emiel Van der Plas, Oscar Mammoliti, Christel Jeanne Marie Menet, Giovanni Alessandro Tricarico, Ann De De Blieck, Caroline Martine Andrée Marie Joannesse, Hans Kelgtermans, Tom Roger Lisette De Munck
  • Publication number: 20140378424
    Abstract: The present invention relates to a method of reducing the body weight of a subject by administering an effective amount of an estrogen receptor modulator (ERM), optionally, in combination with an anti-obesity or weight loss agent.
    Type: Application
    Filed: December 31, 2012
    Publication date: December 25, 2014
    Inventors: Alexey G Ryazanov, Alexander V. Chikunov
  • Publication number: 20140374516
    Abstract: Disclosed is a process for the preparation of drug/carrier inclusion composites which involves co-grinding the mixture of drug and carrier powders in a fluid-jet mill, in particular one using air or nitrogen as the fluid, which is suitably modified to allow mechanical fusion of the powders.
    Type: Application
    Filed: January 25, 2013
    Publication date: December 25, 2014
    Applicant: MICRO-MACINAZIONE S.A.
    Inventors: Fabio Carli, Piero Iamartino, Milko Leone
  • Publication number: 20140371207
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
    Type: Application
    Filed: December 13, 2013
    Publication date: December 18, 2014
    Applicants: Kyowa Hakko Kirin Co., Ltd., Millennium Pharmaceuticals, Inc.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Geraldine C.B. Harriman, Kenneth G. Carson, Shomir Ghosh, Amy M. Elder, Karen M. Mattia
  • Publication number: 20140364421
    Abstract: [Problem] A compound which is useful as an IK1 channel activator is provided. [Means for Solution] As a result of studies on the IK1 channel activator, the present inventors have found that a benzothiophene compound shows effectiveness on visceral pain, inflammatory pain, osteoarthritis pain, neuropathic pain, or fibromyalgia, thereby completing the invention. A compound of the invention has an IK1 channel activation effect, and can also be used as an agent for preventing and/or treating visceral pain, inflammatory pain, osteoarthritis pain, neuropathic pain, or fibromyalgia. In addition, the IK1 channel activator can be used as an agent for preventing and/or treating inflammatory pain, osteoarthritis pain, neuropathic pain, and fibromyalgia.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 11, 2014
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Tsukasa ISHIHARA, Kazuhiro IKEGAI, Ikumi KURIWAKI, Hiroyuki HISAMICHI, Nobuaki TAKESHITA, Ryuichi TAKEZAWA
  • Publication number: 20140343041
    Abstract: The present invention provides topical ophthalmic formulations comprising a combination of one or more antihistamine agents and optionally one or more vasculature modifying agents such as a ? adrenergic receptor antagonist. Also provided are methods of using the formulations of the invention for treating and/or preventing symptoms associated with migraine headache, and for reducing the frequency, severity and duration of migraine attacks.
    Type: Application
    Filed: March 13, 2014
    Publication date: November 20, 2014
    Inventors: Matthew J. Chapin, Richard Abelson
  • Publication number: 20140329802
    Abstract: The purpose is to provide a compound which has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. A tetrahydrobenzothiophene compound of the following formula (I) has NPT-IIb inhibitory action and can be used as an agent for treating and/or preventing hyperphosphatemia: wherein, R1 represents —O-lower alkyl, -lower alkylene-phenyl, or the like; R2 and R3 are the same as or different from each other and represent H, lower alkyl, cycloalkyl, aryl, heteroaryl or the like, or, R2 and R3 may be combined with a nitrogen atom to which they bind to form 5- to 7-membered saturated cyclic amino; R4's are the same as or different from each other and represent halogen, lower alkyl; and n represents 0 to 2.
    Type: Application
    Filed: March 28, 2014
    Publication date: November 6, 2014
    Applicant: Astellas Pharma Inc.
    Inventors: Shunichiro HACHIYA, Masanori Miura, Yoshimasa Imamura, Daisuke Kaga, Ippei Sato, Hiroyuki Moritomo, Koji Kato, Kazuhiro Terai, Yoh Terada
  • Publication number: 20140329859
    Abstract: The present invention relates to ionic silicone hydrogel polymers displaying improved thermal stability. More specifically, the present invention relates to a polymer formed from reactive components comprising at least one silicone component and at least one ionic component comprising at least one anionic group. The polymers of the present invention display good thermal stability and desirable protein uptake.
    Type: Application
    Filed: July 18, 2014
    Publication date: November 6, 2014
    Inventors: Ranganath Raja, Sharmila Muthukrishnan, C. Surendran, R. Sridhara, Shivkumar Mahadevan, Thomas L. Maggio, Azaam Alli, Scott L. Joslin
  • Publication number: 20140322305
    Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.
    Type: Application
    Filed: July 10, 2014
    Publication date: October 30, 2014
    Inventor: John Daniel Dobak
  • Publication number: 20140303091
    Abstract: Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof topical ophthalmic compositions containing norketotifen.
    Type: Application
    Filed: April 15, 2014
    Publication date: October 9, 2014
    Inventors: A.K. Gunnar Aberg, Keith Johnson
  • Publication number: 20140302153
    Abstract: Methods of the prophylaxis of the development of allergy in a patient at risk of sensitization to an antigen(s) or allergen(s) due to impaired gastrointestinal functions include administering a mast cell inhibitor, e.g., ketotifen, e.g., ketotifen fumarate. Methods for prophylactically treating, reducing, delaying or controlling gastrointestinal disorders include administering a mast cell stabilizer, e.g., ketotifen to a patient in need thereof. Pharmaceutical preparation, composition for use in methods described, are also disclosed. Also disclosed are methods of prophylaxis or treating gastrointestinal and esophageal inflammation, and methods for the prophylaxis of the development of additional allergies to a newly introduced substance in a patient with a preexisting allergy. Such methods include delivery of a mast cell stabilizer, e.g., ketotifen. Oral and topical administration are contemplated within the scope of the methods.
    Type: Application
    Filed: April 7, 2014
    Publication date: October 9, 2014
    Applicant: MASTCELL PHARMACEUTICALS, INC.
    Inventor: Dennis PENN
  • Patent number: 8828992
    Abstract: Provided are a substituted azole derivative and pharmaceutically acceptable salts thereof, a pharmaceutical composition including an effective amount of the derivative, and a method for treating Parkinson's disease in a mammal including administering an effective amount of the compound to the mammal. The azole derivative of the following Formula (I) and pharmaceutically useful salts thereof have an efficacy against Parkinson's disease from inhibitory effects of the activity of MAO-B.
    Type: Grant
    Filed: February 25, 2010
    Date of Patent: September 9, 2014
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Cheol-Hyoung Park, Hye-Kyung Min, Mi-Jung Lim, Ji-Won Lee, Jin-Yong Chung, Choon-Ho Ryu, Yeo-Jin Yoon, Mi-Kyung Ji, Joo-Young Park
  • Publication number: 20140243329
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein Y, R1, R2, R3, R4, RA, and RB are defined herein.
    Type: Application
    Filed: May 7, 2014
    Publication date: August 28, 2014
    Applicant: Janssen Pharmaceutica, NV
    Inventor: Jay M Matthews
  • Patent number: 8809331
    Abstract: Specific Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein m, X, R1, R2, R3, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: August 19, 2014
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Anthony Estrada, Janet L. Gunzner-Toste, Daniel Shore, Zachary Kevin Sweeney, Shumei Wang, Guiling Zhao
  • Patent number: 8785383
    Abstract: The present invention is directed to methods of treating or preventing the development of obesity by administering compounds that stabilize mast cells. In addition, it includes pharmaceutical compositions which have both a mast cell stabilizer and instructions regarding the use of the stabilizer in treating or preventing obesity.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: July 22, 2014
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Guo-Ping Shi
  • Patent number: 8778971
    Abstract: The methods disclosed herein relate to the treatment of skin infections in dogs, by administering a therapeutically effective amount of norketotifen. Therapeutic antimicrobial activity of norketotifen against Malassezia sp. is described.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: July 15, 2014
    Assignee: Bridge Pharma, Inc.
    Inventors: A.K. Gunnar Aberg, Vincent B. Ciofalo
  • Patent number: 8765787
    Abstract: Self-preserving ophthalmic formulations containing norketotifen and methods of making the same and the use thereof in patients suffering from xerophthalmia are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof, self-preserving topical ophthalmic formulations containing norketotifen, free from any added preservative.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: July 1, 2014
    Assignee: Bridge Pharma, Inc.
    Inventors: A.K. Gunnar Aberg, Keith Johnson
  • Patent number: 8741930
    Abstract: Methods of using a cycloheptathiophene compound for the treatment of xerophthalmia are described, as are formulations and compositions for such treatment.
    Type: Grant
    Filed: December 24, 2008
    Date of Patent: June 3, 2014
    Assignee: Bridge Pharma, Inc.
    Inventors: A. K. Gunnar Aberg, Keith Johnson
  • Patent number: 8729068
    Abstract: The purpose is to provide a compound which has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. A tetrahydrobenzothiophene compound of the following formula (I) has NPT-IIb inhibitory action and can be used as an agent for treating and/or preventing hyperphosphatemia: wherein, R1 represents —O-lower alkyl, -lower alkylene-phenyl, or the like; R2 and R3 are the same as or different from each other and represent H, lower alkyl, cycloalkyl, aryl, heteroaryl or the like, or, R2 and R3 may be combined with a nitrogen atom to which they bind to form 5- to 7-membered saturated cyclic amino; R4's are the same as or different from each other and represent halogen, lower alkyl; and n represents 0 to 2.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: May 20, 2014
    Assignee: Astellas Pharma Inc.
    Inventors: Shunichiro Hachiya, Masanori Miura, Yoshimasa Imamura, Daisuke Kaga, Ippei Sato, Hiroyuki Moritomo, Koji Kato, Kazuhiro Terai, Yoh Terada
  • Publication number: 20140135296
    Abstract: The invention provides methods of treating autophagy mediated diseases and disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits. In one embodiment, the invention provides a method of determining whether a subject suffers from, or is at risk of developing, and autophagy mediated disease state and/or condition by evaluating LC3 levels.
    Type: Application
    Filed: May 10, 2012
    Publication date: May 15, 2014
    Inventors: Vojo Deretic, Eliseo Castillo, Steven Bradfute, Larry A. Sklar
  • Publication number: 20140120121
    Abstract: The methods disclosed herein relate to the treatment of atopic inflammatory disorders, such as dermal or pulmonary atopic inflammatory disorders, in humans, by administering a therapeutically effective amount of ractopamine.
    Type: Application
    Filed: January 18, 2013
    Publication date: May 1, 2014
    Applicant: BRIDGE PHARMA, INC.
    Inventors: A.K. Gunnar Aberg, Vincent B. Ciofalo
  • Patent number: 8710083
    Abstract: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein Y, L, X1, X2, Z, R3, R4, and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: April 29, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Jun Jiang, Zhi-Qiang Xia, Junyi Zhang, Gary Bohnert, Shoujun Chen, Yu Xie
  • Publication number: 20140113936
    Abstract: The methods disclosed herein relate to the treatment of skin infections in dogs, by-administering a therapeutically effective amount of norketotifen. Therapeutic antimicrobial activity of norketotifen against Malassezia sp. is described.
    Type: Application
    Filed: September 12, 2013
    Publication date: April 24, 2014
    Applicant: BRIDGE PHARMA, INC.
    Inventors: A.K. Gunnar Aberg, Vincent B. Ciofalo
  • Publication number: 20140107085
    Abstract: The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention.
    Type: Application
    Filed: October 10, 2013
    Publication date: April 17, 2014
    Applicant: The Trustees of The University of Pennsylvania
    Inventors: Trevor M. Penning, Adegoke O. Adeniji, Michael C. Burns, Jeffrey Winkler, Barry Twenter
  • Publication number: 20140105957
    Abstract: The present invention relates to an ocular polymer delivery composition comprising at least one ophthalmologic agent dispersed in at least one biodegradable polymer, wherein the polymer comprises at least one of a poly (ester amide) (PEA) having a chemical formula described by structural formula (I).
    Type: Application
    Filed: May 2, 2012
    Publication date: April 17, 2014
    Applicant: DSM IP ASSETS B.V.
    Inventors: Astrid Franken, George Mihov, Jens Christoph Thies
  • Publication number: 20140072571
    Abstract: Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.
    Type: Application
    Filed: March 11, 2013
    Publication date: March 13, 2014
    Applicant: TETHYS BIOSCIENCE, INC.
    Inventors: Mickey S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Publication number: 20140066451
    Abstract: The claimed subject matter is directed to certain thioxanthene derivatives and phenothiazine derivatives suitable for use as anti-infective agents, in particular, for the treatment of infectious diseases. The claimed subject matter furthermore relates to compositions including said anti-infective agents.
    Type: Application
    Filed: November 4, 2013
    Publication date: March 6, 2014
    Applicant: BKG PHARMA APS
    Inventor: Birgit Kjaeldgaard GIWERCMAN
  • Publication number: 20140011843
    Abstract: Ophthalmic compositions and methods of preparing such compositions are disclosed.
    Type: Application
    Filed: May 15, 2013
    Publication date: January 9, 2014
    Applicant: Johnson & Johnson Vision Care, Inc.
    Inventors: Shivkumar Mahadevan, Frank Molock, Vandeeta Khanolkar
  • Publication number: 20140011774
    Abstract: This invention provides pharmaceutical compositions comprising combination of SARM compounds and antiresorptive agents such as SERM compounds, including, inter-alia, Raloxifene, and uses thereof for treating osteoporosis and associated diseases.
    Type: Application
    Filed: March 13, 2013
    Publication date: January 9, 2014
    Inventors: James T. DALTON, Duane D. Miller, Juhyun Kim, Mitchell S. Steiner